Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Baxter
AstraZeneca
Moodys
Harvard Business School
McKinsey

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR MIRABEGRON


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Mirabegron

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00410514 ↗ A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) Completed Astellas Pharma Inc Phase 2 2006-12-01 This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.
NCT00662909 ↗ A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Completed Astellas Pharma Inc Phase 3 2008-03-28 The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder
NCT00688688 ↗ Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Completed Astellas Pharma Inc Phase 3 2008-04-25 The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
NCT00689104 ↗ Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Completed Astellas Pharma Inc Phase 3 2008-04-28 The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
NCT00750620 ↗ A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment Completed Astellas Pharma Inc Phase 1 2008-09-01 The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment.
NCT00776516 ↗ Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers Completed Astellas Pharma Inc Phase 1 2008-10-01 The objective of the study is to assess the PK, safety and tolerability of a single dose of mirabegron alone and in combination with repeat doses of rifampin, a potent CYP3A4 inducer.
NCT00840645 ↗ A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients Completed Astellas Pharma Inc Phase 3 2008-12-01 The study is intended to test the safety, tolerability, and efficacy of long-term treatment with YM178 in patients with overactive bladder symptoms.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mirabegron

Condition Name

Condition Name for Mirabegron
Intervention Trials
Overactive Bladder 29
Healthy Subjects 13
Urinary Bladder, Overactive 12
Pharmacokinetics of Mirabegron 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mirabegron
Intervention Trials
Urinary Bladder, Overactive 58
Urologic Diseases 8
Urinary Bladder Diseases 7
Syndrome 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mirabegron

Trials by Country

Trials by Country for Mirabegron
Location Trials
United States 323
Canada 59
Japan 20
Germany 19
Netherlands 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mirabegron
Location Trials
Maryland 14
California 14
Florida 13
New York 13
Washington 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mirabegron

Clinical Trial Phase

Clinical Trial Phase for Mirabegron
Clinical Trial Phase Trials
Phase 4 31
Phase 3 19
Phase 2/Phase 3 2
[disabled in preview] 56
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mirabegron
Clinical Trial Phase Trials
Completed 81
Recruiting 15
Unknown status 10
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mirabegron

Sponsor Name

Sponsor Name for Mirabegron
Sponsor Trials
Astellas Pharma Inc 39
Astellas Pharma Europe B.V. 14
Astellas Pharma Global Development, Inc. 5
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mirabegron
Sponsor Trials
Other 87
Industry 77
U.S. Fed 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
AstraZeneca
Johnson and Johnson
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.